Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine for Hemodynamic Response to Intubation
NCT07348159Completed
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial in 19p13.3 microduplication syndrome comparing Placebo (Normal Saline) with Nalbuphine 0.2 mg/kg (2 arms). Primary endpoint: Mean Arterial Pressure change at 5 months. Started Mar 2024; status: completed.
02
Drugs
nalbuphine
03
Conditions
19p13.3 microduplication syndrome
Beyond the preview
Go deeper on NCT07348159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348159.